For a short explanation of why the committee made the 2019 recommendations and how they might affect practice, see the rationale and impact section on starting antihypertensive drug treatment. Full details of the evidence and the committee's discussion are in evidence review C: initiating treatment. Monitoring treatment and blood pressure targets For specific recommendations on blood pressure control in people with other conditions or who are pregnant, see also the NICE guidelines on chronic kidney disease, type 1 diabetes and hypertension in pregnancy. 1.4.15 Use clinic blood pressure measurements to monitor the response to lifestyle changes or drug treatment in people with hypertension. [2019] 1.4.16 Measure standing as well as seated blood pressure (see recommendation 1.1.6) in people with hypertension and: with type 2 diabetes or with symptoms of postural hypotension or aged 80 and over. In people with a significant postural drop or symptoms of postural hypotension, treat to a blood pressure target based on standing blood pressure. [2019] 1.4.17 Advise people with hypertension who choose to self-monitor their blood pressure to use HBPM. (NHS England is supporting the use of HBPM through the blood pressure@home scheme.) [2019] 1.4.18 Consider ABPM or HBPM, in addition to clinic blood pressure measurements, for people with hypertension identified as having a white-coat effect or masked hypertension (in which clinic and non-clinic blood pressure results are conflicting). Be aware that the corresponding measurements for ABPM and HBPM are 5 mmHg lower than for clinic measurements (see recommendation 1.2.8 for diagnostic thresholds). 1.4.19 For people who choose to use HBPM, provide: training and advice on using home blood pressure monitors information about what to do if they are not achieving their target blood pressure. 